SecBot SecBot
144 ·Filed Aug 10, 2026

ONC

BeOne Medicines Ltd.
BEARISH
Impact 6/10
Horizondays Processed3mo ago SEC0001950047-26-007895
Form 144, notice of proposed sale of securities
Actionable Insight ▼ Bearish

CEO is executing a massive pre-arranged selling plan, with over $220M in sales already completed in the past month. The 10b5-1 plan provides legal cover but the magnitude is unusual for a $39.6B company. Monitor for any acceleration of selling or additional Form 144 filings. The stock's OTC listing and mixed institutional sentiment (4 trims, 2 near-exits) add to the caution.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$359.27
T+0 close · Aug 10, 2026 · via day close
Latest settled
+5.15%
T+60 · $377.78
Vs SPY
+5.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $359.27entry
  2. T+1 · 3mo ago −0.06%α −0.31% · $359.05
  3. T+5 · 3mo ago +2.75%α +3.15% · $369.15
  4. T+20 · 2mo ago −2.30%α −1.24% · $351.00
  5. T+60 · 13d ago +5.15%α +5.64% · $377.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Chairman and CEO John Oyler filed a Form 144 on August 10, 2026, signaling intent to sell approximately $83.9 million worth of BeOne Medicines (ONC) ADS shares. The filing covers shares acquired via vested stock options and founder shares, and is part of a pre-arranged 10b5-1 trading plan that has already generated over $220 million in sales since mid-July 2026. While the 10b5-1 plan provides some cover, the sheer scale of selling by the CEO is a notable signal.

Key Facts

  • CEO John Oyler filed Form 144 to sell ADS shares valued at approximately $83.9 million.
  • The filing covers 229,115 shares acquired from vested stock options (March 2025) and 11,695 founder shares (October 2014).
  • Oyler has already sold ~$220 million in ONC ADS shares since July 10, 2026 under a 10b5-1 plan.
  • Recent 10b5-1 sales include: $52.99M (Jul 16), $40.89M (Jul 14), $36.36M (Jul 15), $20.16M (Jul 17).
  • The filing also includes sales from the Pan-Oyler Foundation, adding to total insider selling pressure.
  • Market cap is $39.6B; the proposed sale represents ~0.2% of market cap, but cumulative recent sales exceed 0.5%.
  • Institutional activity shows 4 trims and 2 near-exits among top holders in Q2 2026.

Financial Impact

Proposed sale of ~$83.9M in ADS shares by CEO; cumulative 10b5-1 sales since July 10 exceed $220M.

dilutioninsider selling volume

Risk Factors

  • CEO selling at scale may signal lack of confidence in near-term valuation or fundamentals.
  • Cumulative insider selling >0.5% of market cap in 30 days is elevated.
  • OTC listing reduces liquidity and may amplify price impact of large sales.
  • Institutional trimming and near-exits suggest some sophisticated holders are reducing exposure.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-007895
Document: 0001950047-26-007895-index.html0001950047-26-007895
Document: 0001950047-26-007895.txt0001950047-26-007895

Track record

27 reports on ONC

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +12.55% at T+60 after the Aug 5, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $416.54 Now $411.29 −1.26% settles Nov 23
  2. Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $419.98 Now $411.29 −2.07% settles Nov 18
  3. Nov 6, 202610d ago 144 Neutral 2/10 Entry $417.33 to $411.29 Now $411.29 −1.45% ▼ −1.45% +0.25% vs SPY
  4. Nov 5, 202611d ago 144 Neutral 2/10 Entry $406.96 to $416.54 Now $411.29 +1.06% ▲ +2.35% −0.24% vs SPY
  5. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $387.25 to $415.96 Now $411.29 +6.21% ▲ +7.41% +4.12% vs SPY
  6. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $377.78 to $419.98 Now $411.29 +8.87% ▲ +11.17% +12.08% vs SPY
  7. Oct 2, 20266w ago Insider Cluster Bearish 5/10 Entry $361.65 to $350.40 Now $411.29 −13.73% ▲ +3.11% +3.53% vs SPY
  8. Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $368.08 to $365.27 Now $411.29 +11.74% ▼ −0.76% +0.42% vs SPY
  9. Sep 10, 20269w ago Insider Cluster Neutral 3/10 Entry $346.51 to $350.84 Now $411.29 +18.69% ▲ +1.25% +1.47% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $358.26 to $353.83 Now $411.29 +14.80% ▼ −1.24% −0.03% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (11h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026